Evidence map›Paper›PMID 41104595›Full record

ArticleFEBS letters2026

CCT4 promotes tunneling nanotube formation.

Miyu Enomoto, Akiko Asada, Taro Saito, Kanae Ando

Abstract read
In one paragraph

Article in FEBS letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Miyu EnomotoDepartment of Biological Sciences, School of Science, Graduate School of Science, Tokyo Metropolitan University, Japan.
Akiko AsadaDepartment of Biological Sciences, School of Science, Graduate School of Science, Tokyo Metropolitan University, Japan.
Taro SaitoDepartment of Biological Sciences, School of Science, Graduate School of Science, Tokyo Metropolitan University, Japan.
Kanae AndoDepartment of Biological Sciences, School of Science, Graduate School of Science, Tokyo Metropolitan University, Japan.ORCID 0000-0002-3956-276X

Funding

Japan Agency for Medical Research and Development JP24wm0625509Japan Society for the Promotion of Science 24K02860Takeda Science FoundationTokyo Metropolitan University, TMU strategic research fund
6 · The paper itself

Abstract

Tunneling nanotubes (TNTs) are membranous tunnel-like structures that mediate cell-to-cell communication, although the molecular mechanisms of TNT formation are not fully understood. T-complex protein 1 subunit delta (CCT4) serves as a component of the chaperonin-containing TCP1 complex (TRiC) and also functions as a monomer. Here, we report that monomeric CCT4 promotes TNT formation in mammalian cultured cells. The expression of GFP-CCT4 proteins, which are not incorporated into the chaperonin oligomer, induces the formation of nanotubes containing actin fibers and mitochondria. CCT4 proteins are transported intercellularly via these nanotubes. The expression of monomeric CCT4 enhances microtubule dynamics and increases tubulin-containing TNTs. Our results suggest a newly identified function of monomeric CCT4 in TNT formation. Impact statement Tunneling nanotubes (TNTs) play critical roles in various physiological and pathological conditions. TNTs vary in their morphology and cytoskeleton. We found that cells expressing monomeric CCT4 generate many thick TNTs with tubulin. Our results suggest that CCT4 drives the formation of microtubule-containing TNTs.

Indexed as

Chaperonin Containing TCP-1NanotubesAnimalsCell CommunicationCell Membrane StructuresHumansMicrotubulesMitochondriaTubulinChaperonin Containing TCP-1TubulinTunneling NanotubesCCT4intercellular protein transportmicrotubule dynamicstunneling nanotube

Identifiers

PMID41104595
PMCPMC12793717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.